Table 1 Glioblastoma multiforme classification by The Cancer Genome Atlas and World Health Organization
From: Combination therapy to checkmate Glioblastoma: clinical challenges and advances
Sub-class | Genetic markers | Median survival (months) | References |
|---|---|---|---|
Classical | CDKN2A, EGFR, NES, PTEN, Notch and SHH pathway | 12.2 | [18] |
Mesenchymal | NF1, PTEN, TP53, TNF, NF-kB pathway | 11.8 | [18] |
Proneural | PDGFRA, IDH1, PIK3A/PIK3R1, CDKN2A, PTEN, SOX, DCX, DLL3, ASL1, TCF4 | 11.3 | [18] |
Neural | EGFR, NEFL, GABRA1, SYT1, SLC12A5 | 13.1 | [18] |
Glioblastoma, IDH1 wild type | TERT, TP53, EGFR, PTEN | 9.9 | [21] |
Glioblastoma, IDH1 mutant | TERT, TP53, ATRX | 15 | [21] |